

Gerald C So

gcso@iu.edu | (206) 234-6537 | linkedin.com/in/Gerald-So
Indianapolis, IN

PROFESSIONAL SUMMARY

I am seeking to leverage my expertise in clinical trial conduct and extensive knowledge in clinical pharmacology for the role of a clinical pharmacologist. My aim is to advance my skills in quantitative pharmacology, applying a model-informed approach to optimize clinical trial design and navigate regulatory challenges, ultimately contributing to improved patient outcomes.

SKILLS

- | | | |
|---|--|---------------------------|
| • Clinical trial conduct | • Physiologically-based PK modeling (PBPK) | • Strong work ethic |
| • Regulatory submissions | • Population PK (basic understanding) | • Attention to details |
| • Noncompartmental analysis (NCA) | • Scientific writing | • Effective communication |
| • <i>In vitro</i> drug-drug interaction study | | • Project management |
| | | • Growth mindset |

Software

Phoenix WinNonlin, Simcyp, RStudio, GraphPad Prism, REDCap, EndNote, and Microsoft 365.

Languages

Fluent in English and Cantonese (native). Intermediate in Mandarin and Japanese. Basic in Korean.

WORK HISTORY

Clinical Pharmacology Intern

Eli Lilly, Indianapolis, IN

Anticipated Apr 2024 – Jun 2024

- Investigate the effect of renal impairment on pharmacokinetics [anticipated project]

T32 Post-Doctoral Clinical Pharmacology Fellow

Indiana University, Indianapolis, IN

Jul 2022 – Present

- Conduct a Phase 1 clinical trial, collaborating with study site, drug supply, and trial coordinators
- Prepare regulatory submissions for FDA IND, NIH research progress report, and IRB
- Assess the impact of cannabidiol on tacrolimus PK with parameters obtained from NCA as well as any treatment-emergent adverse events (TEAEs) for an interim analysis
- Analyze and interpret kinetic results from an *in vitro* drug-drug interaction experiment
- Predict the magnitude of a drug-drug interaction in transplant recipients with chronic kidney disease using a PBPK model
- Collaborate with bioinformaticians to investigate the immunosuppressive mechanism of cannabidiol using transcriptomics
- Train technicians to perform *ex vivo* luminescence-based proliferation assay
- Curate abstracts using clinical judgment to build a machine learning knowledge base

PROFESSIONAL DEVELOPMENT

Phoenix WinNonlin PK/PD Modeling Certification Course (Certara; Online)

Mar 2024 – Present

NCA Conceptual Course (Certara; Online)

Jan 2024 – Mar 2024

Simcyp Hands-On Workshop (Certara; Boston, MA)

Jul 2023

AWARDS / GRANTS

Presidential Trainee Award

American Society of Clinical Pharmacology & Therapeutics (ASCPT)

Mar 2024

PUBLICATIONS

So GC, Cheng YH, Gisch DL, Lu JB, Koyama S, McClara K, Dexter PR, Sharfuddin AA, Tillman EM, Beamon TR, Cowser ZJ, Stuart JS, Desta Z, Eadon MT. “Rationale and design of the drug-gene-nutraceutical interactions study of cannabidiol and tacrolimus.” [Submitted to *Pharmaceutics*]

So GC, Lu JB, Cheng YH, Gisch DL, Koyama S, Beamon TR, Eadon MT, Desta Z. “Inhibition of tacrolimus metabolism by cannabidiol and its metabolites *in vitro*.” [Planned Submission to *Drug Metabolism and Disposition* Apr 2024]

EDUCATION

Doctor of Pharmacy

Purdue University, West Lafayette, IN

May 2022